BLRX (BLRX) Stock Price & Analysis
BLRX (BLRX) fell 1.40% to USD 2.82 as of July 25, 2026 at 06:49 UTC, according to Nexqual real-time market data.
BLRX last closed at USD 2.86; the session ranged USD 2.82–3.04 on volume of 2,416 shares. Market capitalization is $12.69M, with a 52-week range of USD 2.15–4.69 (NCM). Source: Nexqual, July 25, 2026 at 06:49 UTC.
Key Statistics (as of July 25, 2026 at 06:49 UTC)
| Price | USD 2.82 |
|---|---|
| Change | ▼ 1.40% (down) |
| Previous Close | USD 2.86 |
| Open | USD 2.86 |
| Day Range | USD 2.82 – 3.04 |
| 52-Week Range | USD 2.15 – 4.69 |
| Volume | 2,416 shares |
| Market Cap | $12.69M |
| Exchange | NCM |
Technical Analysis (BLRX)
Nexqual's technical model rates BLRX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.73 (neutral) |
| vs SMA50 | Below (USD 3.13) |
| MACD | -0.08 (negative) |
Analyst Ratings (BLRX)
Wall Street analysts rate BLRX "None" based on 2 analysts, with a mean price target of USD 17.5 (range USD 12–23), per Nexqual as of July 25, 2026 at 06:49 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 17.5 |
| High Target | USD 23 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (BLRX)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.3 |
| Revenue Estimate | $428,500 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0 vs est -1.04 ▲ beat |
| 2025-12-31 | USD 0 vs est -0.77 ▲ beat |
| 2025-09-30 | USD 0 vs est -0.54 ▲ beat |
| 2025-06-30 | USD 0 vs est -0.53 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:49 UTC.
Financials & Fundamentals (BLRX)
| Total Revenue | $1.40M |
|---|---|
| Revenue Growth (YoY) | +87.10% |
| Gross Margin | +79.24% |
| Operating Margin | -629.77% |
| Profit Margin | +0.00% |
| ROE | -46.72% |
| Debt / Equity | 43.53 |
| Current Ratio | 1.58 |
| Total Cash | $17.35M |
| Total Debt | $9.07M |
| Free Cash Flow | $-5.49M |
Source: Nexqual, July 25, 2026 at 06:49 UTC.
Financial Health Score (BLRX)
Nexqual rates BLRX's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:49 UTC.
| Growth | Critical — Revenue -96% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $17M cash vs $9M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -47%, ROA -16.6% |
Ownership (BLRX)
| Insider Ownership | +3.91% |
|---|---|
| Institutional Ownership | +0.45% |
| Shares Outstanding | 4.35M |
| Float | 4.16M |
| Short % of Float | +3.36% |
Source: Nexqual, July 25, 2026 at 06:49 UTC.
Leadership (BLRX)
BLRX is led by Philip A. Serlin (age 65), Chief Executive Officer, per Nexqual as of July 25, 2026 at 06:49 UTC.
| Chief Executive Officer | Philip A. Serlin (age 65) |
|---|---|
| Chief Financial Officer | Mali Zeevi (age 49) |
| Treasurer & Budgetary Control Director | Raziel Fried |
Major Backers & Investors (BLRX)
Notable institutional backers of BLRX include Xtx Topco Ltd, according to Nexqual as of July 25, 2026 at 06:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Xtx Topco Ltd | 0.25% |
Source: Nexqual, July 25, 2026 at 06:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CANF | Can-Fite Biopharma Ltd | USD 3.19 | ▼ 3.33% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.41 | ▼ 2.43% |
| PLX | Protalix BioTherapeutics, Inc. | USD 2.37 | ▲ 0% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.52 | ▼ 10.59% |
| RDHL | Redhill Biopharma Ltd. | USD 0.63 | ▼ 7.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:49 UTC. This page is informational and not investment advice.